# Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

> **NCT01458977** · PHASE4 · COMPLETED · sponsor: **Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia** · enrollment: 48 (actual)

## Conditions studied

- HIV
- Dyslipidemia

## Interventions

- **DRUG:** Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01458977
- **Lead sponsor:** Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01458977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01458977, "Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01458977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*